Wells Fargo maintained an Outperform rating on Gilead Sciences (NASDAQ: GILD) with a price target of $87-$91. Analyst Brian Abrahams ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Analyst Comments Analyst EPS Change Analyst EPS View

Gilead (GILD) Q1 'One of Most Impressive Beats in Biopharma History' - Piper Jaffray April 23, 2014 8:51 AM Goldman Sachs Comments on Gilead Sciences (GILD) Q1April 23, 2014 7:46 AM Gilead Sciences (GILD) Q1 'As Good as it Gets' - NomuraApril 23, 2014 7:39 AM Gilead Sciences, Inc. (GILD) Tops Q1 EPS by 61c, Offers GuidanceApril 22, 2014 4:30 PM